The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Modeling the cost-effectiveness of adjuvant osimertinib in resected EGFR-mutant non-small cell lung cancer patients.
 
Christopher Lemmon
No Relationships to Disclose
 
Emily Craig Zabor
No Relationships to Disclose
 
Nathan A. Pennell
Consulting or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Cota Healthcare; G1 Therapeutics; Genentech; Inivata; Janssen Oncology; Lilly; Merck; Mirati Therapeutics; Pfizer; Viosera Therapeutics; Xencor
Research Funding - Altor BioScience (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Genentech (Inst); Heat Biologics (Inst); Jounce Therapeutics (Inst); Loxo (Inst); Merck (Inst); Mirati Therapeutics (Inst); Pfizer (Inst); Spectrum Pharmaceuticals (Inst); WindMIL (Inst)